Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-Year follow-up results of the French Adjuvant Study Group 01 trial

Journal of Clinical Oncology

Volumn 21, Issue 2, 2003, Pages 298-305

  Fumoleau, Pierre ^a   Kerbrat, Pierre ^b   Romestaing, Pascale ^b   Fargeot, Pierre ^b   Brémond, Alain ^b   Namer, Moïse ^b   Schraub, Simon ^b   Goudier, Marie Jo ^b   Mihura, Jeanne ^b   Monnier, Alain ^b   Clavère, Pierre ^b   Serin, Daniel ^b   Seffert, Philippe ^b   Pourny, Christiane ^b   Facchini, Thomas ^b   Jacquin, Jean Philippe ^b   Sztermer, Jean François ^b   Datchary, Jean ^b   Ramos, René ^b   Luporsi, Elisabeth ^b  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; ANTINEOPLASTIC AGENT; FEC PROTOCOL;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG FATALITY; FOLLOW UP; HEART DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; THORAX WALL; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; ADULT; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; FEMALE; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RISK FACTOR; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PREMENOPAUSE; RISK FACTORS; SURVIVAL RATE;

EID: 0037440048     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.148     Document Type: Article

References (38)

1. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer, the results of 20 years of follow-up. N Engl J Med 332:901-906, 1995
2. Fisher B, Cardone P, Economou SG, et al: 1-phenylalanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med 292:117-122, 1975
3. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31, 000 recurrences and 24,000 deaths among 75, 000 women. Lancet 339:71-85, 1992
4. Tormey DC: Adriamycin in breast cancer: An overview of studies. Cancer Chemother Rep 6:319-327, 1975
5. Mouridsen HT: Systemic therapy of advanced breast cancer. Drugs 44:17-28, 1992
6. French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 6:679-688, 1988
7. Misset JL, di Palma M, Delgado M, et al: Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration. J Clin Oncol 14:1136-1145, 1996
8. Fisher B, Redmond C, Wickerham DL, et al: Doxorubicin-containing regimens for the treatment of stage II breast cancer. The National Surgical Adjuvant Breast and Bowel Project experience J Clin Oncol 7:572-582, 1989
9. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
10. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 273:542-547, 1995
11. Tancini G, Bonadonna G, Valagussa P, et al: Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1:2-10, 1983
12. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90:1205-1211, 1998
13. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
14. Snedecor GW, Cochran WG: Statistical Methods (ed 7). Ames, Iowa, State University Press, 1980
15. Duncan DB: P-tests and intervals for comparison suggested by the data. Biometrics 31:339-359, 1975
16. Meyer RM, Browman GP, Samosh ML, et al: Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 13:2386-2393, 1995
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135:185-198, 1972
19. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-202, 1972
20. Goldhirsch A, Gelber RD: Randomized perioperative therapy in operable breast cancer: The Ludwig trial V. Recent Results Cancer Res 115:43, 1989
21. Falkson HC, Gray R, Wolberg WH, et al: Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: An Eastern Cooperative Oncology Group phase III study. J Clin Oncol 8:599-607, 1990
22. Schumacher M, Bastert G, Bojar H, et al: Randomized 2 × 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. J Clin Oncol 12:2086-2093, 1994
23. Sauerbrei W, Basten G, Bojar H, et al: Randomized 2 × 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: An update based on 10 years' follow-up. German Breast Cancer Study Group. J Clin Oncol 18:94-101, 2000
24. The International Breast Cancer Study Group: Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 14:1185-1194, 1996
25. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
26. National Institutes of Health Consensus Development Panel: National Institutes of Health consensus development conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
27. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 19:3817-3827, 2001
28. Henderson IC, Berry DA, Demetri G, et al: Improved disease-free survival and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Oncol 17:390, 1998 (abstr)
29. French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602-611, 2001
30. Bonneterre J, Roché H, Kerbrat P, et al: Long-term cardiac follow-up in free of disease patients after receiving 6 FEC 50 vs 6 FEC 100 (FASG-05 trial) as adjuvant chemotherapy for node-positive breast cancer. Proc Am Soc Clin Oncol 21:154, 2002 (abstr)
31. Shapiro CL, Hardenbergh P, Gelman R, et al: Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 16:3493-3501, 1998
32. Italian Multicentre Breast Study with Epirubicin: Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial. J Clin Oncol 6:976-982, 1988
33. Torti FM, Bristow MM, Lum BL, et al: Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 46: 3722-3727, 1986
34. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16:2651-2658, 1998
35. Diamandidou E, Buzdar AU, Smith TL, et al: Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M. D. Anderson Cancer Center experience J Clin Oncol 14:2722-2730, 1996
36. b supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc Am Soc Clin Oncol 18:3, 1999 (abstr)
37. Delaloge S, Di M, Guérin S, et al: Adjuvant doxorubicin, vincristine, cyclophosphamide, fluorouracil (AVCF), for breast cancer: No treatment-related leukemia at 13-year follow-up. Proc Am Soc Clin Oncol 17:449, 1998 (abstr)
38. Decillis A, Anderson S, Bryant J, et al: Acute myeloid leukemia and myelodysplastic syndrome on NSABP B-25: an update. Proc Am Soc Clin Oncol 16:459, 1997 (abstr)